Breaking News
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19%
Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate; shares jump 19% as clinical-stage biotech shows sequential improvement.